Sign In
Buy ASMB
$25.55
+0.330 (+1.31%)
At Close: Jul 24, 2026
Penny Stocks To Buy Now? 6 To Watch With Big News Today
02:33pm, Monday, 19'th Dec 2022 PennyStocks
Hot penny stocks to watch with big news this week.
The post Penny Stocks To Buy Now? 6 To Watch With Big News Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com
Penny Stocks To Buy Now? 6 To Watch With Big News Today
09:33am, Monday, 19'th Dec 2022
Hot penny stocks to watch with big news this week. The post Penny Stocks To Buy Now?
After Plunging 17% in 4 Weeks, Here's Why the Trend Might Reverse for Assembly Biosciences (ASMB)
02:35pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
The heavy selling pressure might have exhausted for Assembly Biosciences (ASMB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stree
After Plunging 17% in 4 Weeks, Here's Why the Trend Might Reverse for Assembly Biosciences (ASMB)
11:18am, Wednesday, 09'th Nov 2022
The heavy selling pressure might have exhausted for Assembly Biosciences (ASMB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stree
NVIDIA To $140? Plus This Analyst Cuts PT On Assembly Biosciences By 82%
02:10pm, Monday, 24'th Oct 2022 Benzinga
Truist Securities cut the price target on Assembly Biosciences, Inc. (NASDAQ: ASMB) from $11 to $2. Assembly Biosciences shares gained 2.6% to trade at $1.58 on Monday.
Mizuho cut the price target f
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2022
02:08pm, Monday, 24'th Oct 2022 Benzinga
Upgrades
Guggenheim upgraded the previous rating for Teladoc Health Inc (NYSE:TDOC) from Sell to Neutral. Teladoc Health earned $0.44 in the second quarter, compared to $0.86 in the year-ago quarter.
Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®
08:00am, Monday, 24'th Oct 2022
Four poster presentations, including two late breaking, highlight breadth and promise of virology portfolio
Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor
08:05pm, Wednesday, 05'th Oct 2022 GlobeNewswire Inc.
Dr. McHutchison will continue to provide strategic counsel as board member and chairman of the Science & Technology Committee of the board Dr. McHutchison will continue to provide strategic counsel as
Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
08:05pm, Tuesday, 09'th Aug 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics t
Assembly Biosciences (ASMB) Upgraded to Strong Buy: Here's Why
04:00pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Assembly Biosciences (ASMB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for August 4th
02:00pm, Thursday, 04'th Aug 2022 Zacks Investment Research
PI, INST and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 4, 2022.
Assembly Biosciences (ASMB) Upgraded to Strong Buy: Here's Why
01:32pm, Thursday, 04'th Aug 2022
Assembly Biosciences (ASMB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for August 4th
10:27am, Thursday, 04'th Aug 2022 Zacks Investment Research
ARI, CB, PI, ASMB and URI have been added to the Zacks Rank #1 (Strong Buy) List on August 4, 2022.
New Strong Buy Stocks for August 4th
07:32am, Thursday, 04'th Aug 2022
ARI, CB, PI, ASMB and URI have been added to the Zacks Rank #1 (Strong Buy) List on August 4, 2022.
Assembly Biosciences Announces Program Reprioritization and Organizational Update
08:05pm, Wednesday, 20'th Jul 2022 GlobeNewswire Inc.
- Discontinues clinical development of vebicorvir, Assembly Bio’s first-generation core inhibitor, based on interim efficacy data from ongoing combination clinical studies
